Billon-Rey S, Beylot M, Mathian B, Patricot M C, Berthezene F, Mornex R, Revol A
Presse Med. 1986 May 24;15(21):965-8.
The usefulness for the diagnosis of Cushing's syndrome of urinary free cortisol and urinary 17-hydroxycorticosteroid (17-OHCS) determination was compared by measuring these substances in 17 normal and 28 obese subjects and in 19 patients with established Cushing's syndrome. These measurements were repeated in 16 obese subjects and 11 Cushing's syndrome patients after oral administration of dexamethasone (2 mg/day for 2 days, then 8 mg/day for 2 days). As a group, the patients with Cushing's syndrome had higher (p less than 0.001) excretion rate of both free cortisol and 17-OHCS, but the values observed in this group overlapped with those of normal and obese subjects. The overlap was not significantly different for free cortisol and 17-OHCS excretion. In each obese subject, oral dexamethasone decreased the urinary excretion rate of both free cortisol and 17-OHCS. Seven out of the eleven patients with Cushing's syndrome had no decrease of urinary free cortisol or 17-OHCS, whereas both values were slightly lower in one and decreased to levels similar to those obtained in obese subjects in the three remaining patients. It is concluded that there is no advantage in measuring free cortisol excretion instead of 17-OHCS excretion, either before of after a pituitary-adrenal suppression test, for the diagnosis of Cushing's syndrome.
通过对17名正常受试者、28名肥胖受试者以及19名确诊为库欣综合征的患者进行尿游离皮质醇和尿17-羟皮质类固醇(17-OHCS)测定,比较了这两种物质对库欣综合征诊断的效用。在16名肥胖受试者和11名库欣综合征患者口服地塞米松后(2毫克/天,共2天,然后8毫克/天,共2天)重复进行这些测量。作为一个整体,库欣综合征患者的游离皮质醇和17-OHCS排泄率均较高(p<0.001),但该组观察到的值与正常和肥胖受试者的值有重叠。游离皮质醇和17-OHCS排泄的重叠无显著差异。在每一名肥胖受试者中,口服地塞米松均降低了游离皮质醇和17-OHCS的尿排泄率。11名库欣综合征患者中有7名尿游离皮质醇或17-OHCS无降低,而在其余3名患者中,这两个值略有降低,降至与肥胖受试者相似的水平。结论是,在垂体-肾上腺抑制试验之前或之后,对于库欣综合征的诊断,测量游离皮质醇排泄而非17-OHCS排泄并无优势。